The Organizing Committee
requires that presenting authors submit their abstracts electronically via this website.
Abstract submissions will only be accepted from the presenting author. All correspondence
regarding the status of the abstract will only be sent to the presenting author. As
in previous years, the abstract and application process has been combined into one
online step. During the online application/abstract process, if you indicate on the
application form that you are the presenting author and intend to submit an abstract,
you will be forwarded to the ABSTRACT SUBMISSION page, providing an opportunity to
upload the abstract. There is no need to complete the application/abstract form until
your abstract is ready for submission.
To submit an abstract click on the SUBMIT
ABSTRACT button
at the bottom of the page and follow the step-by-step directions, which will enable
you to provide the presenting author contact information, answer a few questions,
and then upload the file containing your abstract from the computer system that you
are using to access this website. To ensure your abstract retains any special characters
or formatting, the abstract must be in MICROSOFT WORD format.
Multiple submissions from the same data set will jeopardize abstract acceptance. The
Organizing Committee urges submission of a single abstract from the entire group involved
in the study.
Each applicant may submit a MAXIMUM of two (2) abstracts. If more than two (2) abstracts
are submitted, only the last 2 submissions will be evaluated.
PLEASE NOTE THE ABSTRACT DEADLINE IS MIDNIGHT EASTERN TIME April 13, 2006.
For each accepted abstract, one registration slot will be awarded to the presenting
author. Co-authors of abstracts must complete an application to be considered
for admittance into the Workshop.
Notifications of acceptance and format of presentation (oral or poster presentation)
will be sent out on May 11, 2006. Guidelines for preparing your poster presentations
will be sent if your abstract is accepted.
Upon
notification of acceptance of abstract, the presenting author must REGISTER for the
Workshop by May 23, 2006. Failure
to register on or before the deadline may result in the loss of your acceptance in
the Workshop.
Abstract presenters MAY NOT be changed after acceptance, without consent of the Organizing
Committee.
SAMPLE
ABSTRACT
To view a sample abstract, click
here. The sample form is an Adobe Acrobat document. If your computer cannot read
the sample, please click
here to download Adobe's free Acrobat Reader.
ABSTRACT
GUIDELINES
Format
The
publisher of the abstract book does not allow figures or tables to appear in the submitted
abstract.
-
All abstracts should
be sent as Microsoft Word files.
-
All abstracts should
be typed in English using single-line spacing.
-
All abstracts should
be typed in Arial font at a size of 11 points.
-
Abstracts must not exceed
350 words.
-
Author names and affiliations
should be written as follows, with the presenting author's name underlined:
AN
Author1, AN Author2 and AN Author3
1University of London, London, UK; 2University of Frankfurt, Frankfurt, Germany; and 3University of Paris, Paris, France
The body of the uploaded
abstract submission should not exceed 350 words; this limit excludes the title, authors
and affiliations.
-
Results and conclusions
must be included; it is not acceptable to state that results will be presented.
-
Abstract text may be
divided into the following sections: objectives/aim, methods, results, conclusion(s)/discussion.
-
Tables,
graphs and references must NOT be used.
-
Acknowledgements may
be listed after the abstract.
-
Generic (not trade) names
for drugs should be used and written in full (not denoted by initials).
-
Dosing regimens should
be written in full. For example, TID should be written as three times daily.
Clearly define all concepts
and abbreviations at first use. If English is not your primary language, attempt to
have your abstract reviewed by a native English speaker. To be acceptable, abstracts
shall contain a concise statement of the research. It is recommended that the author
follow the structured format below:
Title (not
included in 350 word limit)
Use a short and concise title that indicates the content of the abstract. Capitalize
the first letter of each word except prepositions, articles, and species names. Species
names should be spelled out at first use. Italicize scientific names of organisms
(example: Staphylococcus aureus). For therapeutic agents, only generic names may be
used (no trade names are permitted in abstract titles).
Authors/Affiliations (not
included in 350 word limit)
Authors' names should be entered using initial(s) for the first and middle names
followed by the full last name, with presenting author underlined (e.g. AN Author1,
AN Author2 and AN Author3).
All author affiliations
should be entered as follows:
1 University of London, London, UK; 2 University of Frankfurt, Frankfurt, Germany;
and 3 University of Paris, Paris, France.
Background
State the problem under investigation or a hypothesis. For therapeutic agents,
only generic names may be used (no trade names are permitted). No figures or tables
are allowed.
Methods
Explain the experimental methods used. For therapeutic agents, only generic names
may be used (no trade names are permitted). No figures or tables are allowed.
Results
List the essential results obtained in summary form, with enough quantitative
data to permit evaluation by reviewers. For therapeutic agents, only generic names
may be used (no trade names are permitted). No figures or tables are allowed.
Conclusion
Summarize the findings. It is unacceptable to use statements such as "the results
will be discussed". For therapeutic agents, only generic names may be used (no trade
names are permitted). No figures or tables are allowed.
ADDITIONAL ABSTRACT INFORMATION
In addition to the uploaded abstract, the following additional information will be
collected on the abstract submission form:
Abstract Category
For purposes of review and programming, abstracts are divided into topical categories.
Selection of the most appropriate category is important as it determines who reviews
your abstract. The Organizing Committee reserves the right to reassign your abstract
to a more appropriate category.
-
Resistance to New Antiretroviral
Agents
-
Mechanisms of HIV Drug
Resistance
-
HIV Pathogenesis, Fitness
and Resistance
-
Clinical Implications
of Resistance
-
Epidemiology
-
New Resistance Technologies
and Interpretations
-
HBV Drug Resistance
- HCV Drug Resistance
Abstract Title (should be the same as in the uploaded abstract)
Use a short and concise title that indicates the content of the abstract. Capitalize the first letter of each word except prepositions, articles, and species names. Species names should be spelled out at first use. Italicize scientific names of organisms (example: Staphylococcus aureus). For therapeutic agents, only generic names may be used (no trade names are permitted in abstract titles).
ABSTRACT EVALUATION
AND SCORING
The Organizing Committee (OC) and 4-6 members of the Scientific Committee (SC)
will review each abstract. The OC evaluates all submitted abstracts. Members of the
SC are selected for abstract categories based upon their individual expertise.
OC and SC members are
instructed to review the abstracts for the quality and originality of the work and
to score them numerically. All reviewers are instructed to abstain from scoring any
abstract on which they are an author/co-author, have a financial or personal conflict
of interest, or do not have the appropriate expertise to evaluate.
Scores for each abstract
are averaged and the standard deviation is calculated to assess variability. If variability
is high, outlier scores are identified and censored.
Abstracts with high variability
in scores are discussed individually.
PUBLISHED ABSTRACT
BOOK
Accepted abstracts will be standardized in font and presentation. Any scientific
error that appears in the submitted abstract will appear in the printed abstract.
Subject to availability,
copies of the Abstract Book will be available for sale after the Conference.
Abstract submission is no longer available.
Copyright © 2006 Informed
Horizons, LLC
All rights reserved, additional copyright information also applies.